Angela Watkins / January 31, 2014
SAN FRANCISCO (CN) – Shareholders can advance claims over “rosy statements” Affymax made about its now-recalled anti-anemia drug Omontys, a federal judge ruled. In a Feb. 23, 2013, statement about the recall, Affymax revealed that 2 percent of patients who used Omontys suffered life-threatening anaphylaxis, which proved fatal for 1 in 100. Omontys was injected to treat
SAN FRANCISCO (CN) – Shareholders can advance claims over “rosy statements” Affymax made about its now-recalled anti-anemia drug Omontys, a federal judge ruled. In a Feb. 23, 2013, statement about the recall, Affymax revealed that 2 percent of patients who used Omontys suffered life-threatening anaphylaxis, which proved fatal for 1 in 100. Omontys was injected to treat
SAN FRANCISCO (CN) – Shareholders can advance claims over “rosy statements” Affymax made about its now-recalled anti-anemia drug Omontys, a federal judge ruled. In a Feb. 23, 2013, statement about the recall, Affymax revealed that 2 percent of patients who used Omontys suffered life-threatening anaphylaxis, which proved fatal for 1 in 100. Omontys was injected to treat
SAN FRANCISCO (CN) – Shareholders can advance claims over “rosy statements” Affymax made about its now-recalled anti-anemia drug Omontys, a federal judge ruled. In a Feb. 23, 2013, statement about the recall, Affymax revealed that 2 percent of patients who used Omontys suffered life-threatening anaphylaxis, which proved fatal for 1 in 100. Omontys was injected to treat
SAN FRANCISCO (CN) – Shareholders can advance claims over “rosy statements” Affymax made about its now-recalled anti-anemia drug Omontys, a federal judge ruled. In a Feb. 23, 2013, statement about the recall, Affymax revealed that 2 percent of patients who used Omontys suffered life-threatening anaphylaxis, which proved fatal for 1 in 100. Omontys was injected to treat